These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 22544804)
1. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Murray KF; Szenborn L; Wysocki J; Rossi S; Corsa AC; Dinh P; McHutchison J; Pang PS; Luminos LM; Pawlowska M; Mizerski J Hepatology; 2012 Dec; 56(6):2018-26. PubMed ID: 22544804 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
3. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ; J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786 [TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Jonas MM; Kelly D; Pollack H; Mizerski J; Sorbel J; Frederick D; Mondou E; Rousseau F; Sokal E Hepatology; 2008 Jun; 47(6):1863-71. PubMed ID: 18433023 [TBL] [Abstract][Full Text] [Related]
7. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients]. Ling N; Zhou Z; Zhang DZ; Ren H Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350 [TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P; Chang TT; Lim SG; Sievert W; Tong M; Arterburn S; Borroto-Esoda K; Frederick D; Rousseau F Hepatology; 2008 Sep; 48(3):750-8. PubMed ID: 18752330 [TBL] [Abstract][Full Text] [Related]
10. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments]. Huang M; Li X; Wu Y; Tao L; Jie Y; Li X; Shi H; Lin G; Yang F; Ao Y; Pang Y; Zhang M; Chong Y Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):266-71. PubMed ID: 25173224 [TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL; Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951 [TBL] [Abstract][Full Text] [Related]
13. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704 [TBL] [Abstract][Full Text] [Related]
14. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. Berg T; Zoulim F; Moeller B; Trinh H; Marcellin P; Chan S; Kitrinos KM; Dinh P; Flaherty JF; McHutchison JG; Manns M J Hepatol; 2014 Apr; 60(4):715-22. PubMed ID: 24295873 [TBL] [Abstract][Full Text] [Related]
16. Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience. Panda C J Assoc Physicians India; 2013 Nov; 61(11):785-8. PubMed ID: 24974488 [TBL] [Abstract][Full Text] [Related]
17. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795 [TBL] [Abstract][Full Text] [Related]
18. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F; Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270 [TBL] [Abstract][Full Text] [Related]
19. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Zeng M; Mao Y; Yao G; Wang H; Hou J; Wang Y; Ji BN; Chang CN; Barker KF Hepatology; 2006 Jul; 44(1):108-16. PubMed ID: 16799983 [TBL] [Abstract][Full Text] [Related]
20. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Peters MG; Andersen J; Lynch P; Liu T; Alston-Smith B; Brosgart CL; Jacobson JM; Johnson VA; Pollard RB; Rooney JF; Sherman KE; Swindells S; Polsky B; Hepatology; 2006 Nov; 44(5):1110-6. PubMed ID: 17058225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]